Melatonin pharmacokinetics in premenopausal and postmenopausal healthy female volunteers

Journal of Clinical Pharmacology

Volumn 48, Issue 2, 2008, Pages 240-245

  Markantonis, Sophia L ^a   Tsakalozou, Eleftheria ^a   Paraskeva, Anteia ^a   Staikou, Chryssoula ^a   Fassoulaki, Argyro ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Age; Female; Melatonin; Pharmacokinetics

Indexed keywords

MELATONIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RELEASE; DRUG RESEARCH; FEMALE; GLUCOSE TOLERANCE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HUMAN EXPERIMENT; MENSTRUAL CYCLE; NORMAL HUMAN; POSTMENOPAUSE; PREMENOPAUSE; SOMNOLENCE; THYROID FUNCTION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BODY MASS INDEX; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HEADACHE; HUMANS; MELATONIN; MENOPAUSE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PREMENOPAUSE; SLEEP DISORDERS; TIME FACTORS;

EID: 38349135092     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007311112     Document Type: Article

References (41)

1. Reiter RJ Melatonin: clinical relevance. Best Pract Res Clin Endocrinol Metab. 2003 ; 17: 273-285.
2. Waldhauser F., Weiszenbacher G., Frisch H., et al. Fall in nocturnal serum melatonin during prepuberty and pubescence. Lancet. 1984 ; 1: 362-365.
3. Waldhauser F., Ehrhart B., Forster E. Clinical aspects of the melatonin action: impact of development, aging and puberty, involvement of melatonin in psychiatric disease and importance of neuroimmunoendocrine interactions. Experientia. 1993 ; 49: 671-681.
4. Zhou JN, Liu RY, van Heerikhuize J., et al. Alterations in the circadian rhythm of salivary melatonin begin during middle-age. J Pineal Res. 2003 ; 34: 11-16.
5. Zhao ZY, Xie Y., Fu YR, et al. Aging and the circadian rhythm of melatonin: a cross-sectional study of Chinese subjects 30-110 yr of age. Chronobiol Int. 2002 ; 19: 1171-1182.
6. Okatani Y., Morioka N., Wakatsuki A. Changes in nocturnal melatonin secretion in perimenopausal women: correlation with endogenous estrogen concentrations. J Pineal Res. 2000 ; 28: 111-118.
7. Vakkuri O., Kivela A., Leppaluoto J., et al. Decrease in melatonin precedes follicle-stimulating hormone increase during peri-menopause. Eur J Endocrinol. 1996 ; 135: 188-192.
8. Aleandri V., Spina V., Morini A. The pineal gland and reproduction. Hum Reprod Update. 1996 ; 2: 225-235.
9. Webley GE, Leidenberger F. The circadian pattern of melatonin and its positive relationship with progesterone in women. J Clin Endocrinol Metab. 1986 ; 63: 323-328.
10. Shibui K., Uchiyama M., Okawa M., et al. Diurnal fluctuation of sleep propensity and hormonal secretion across the menstrual cycle. Biol Psychiatry. 2000 ; 48: 1062-1068.
11. Brzezinski A., Lynch HJ, Seibel MM, et al. The circadian rhythm of plasma melatonin during normal menstrual cycle and in amenorrheic women. J Clin Endocrinol Metab. 1988 ; 66: 891-895.
12. Walters JF, Hampton SM, Ferns GA, et al. Effect of menopause on melatonin and alertness rhythms investigated in constant routine conditions. Chronobiol Int. 2005 ; 22: 859-872.
13. Cagnacci A., Arangino S., Renzi A., et al. Influence of melatonin administration on glucose tolerance and insulin sensitivity of postmenopausal women. Clin Endocrinol (Oxf). 2001 ; 54: 339-346.
14. Bellipanni G., Bianchi P., Pierpaoli W., et al. Effects of melatonin in perimenopausal and menopausal women: a randomized and placebo controlled study. Exp Gerontol. 2001 ; 36: 297-310.
15. Iguchi H., Kato KI, Ibayashi H. Melatonin serum levels and metabolic clearance rate in patients with liver cirrhosis. J Clin Endocrinol Metab. 1982 ; 54: 1025-1027.
16. Cavallo A., Ritschel WA Pharmacokinetics of melatonin in human sexual maturation. J Clin Endocrinol Metab. 1996 ; 81: 1882-1886.
17. Benedetti MS, Whomsley R., Canning M. Drug metabolism in the paediatric population and in the elderly. Drug Discov Today. 2007 ; 12: 599-610.
18. Facciola G., Hidestrand M., von Bahr C. Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes. Eur J Clin Pharmacol. 2001 ; 56: 881-888.
19. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 ; 23: 56-62.
20. Buysse DJ, Reynolds CF III, Monk TH, et al. The Pittsburgh Sleep Quality Index: a New Instrument for Psychiatric Practice and Research. Psychiatry Res. 1989 ; 28: 193-213.
21. Kostoglou-Athanassiou I., Athanassiou P., Treacher DF, et al. Neurohypophysial hormone and melatonin secretion over the natural and suppressed menstrual cycle in premenopausal women. Clin Endocrinol (Oxf). 1998 ; 49: 209-216.
22. Deacon S., Arendt J. Posture influences melatonin concentrations in plasma and saliva in humans. Neurosci Lett. 1994 ; 167: 191-194.
23. Hahm H., Kujawa J., Augsburger L. Comparison of melatonin products against USP's nutritional supplements standards and other criteria. J Am Pharm Assoc (Wash). 1999 ; 39: 27-31.
24. Sastre-Torano J., Rijn-Bikker P., Merkus P., et al. Quantitative determination of melatonin in human plasma and cerebrospinal fluid with high-performance liquid chromatography and fluorescence detection. Biomed Chromatogr. 2000 ; 14: 306-310.
25. Vakkuri O., Leppaluoto J., Kauppila A. Oral administration and distribution of melatonin in human serum, saliva and urine. Life Sci. 1985 ; 37: 489-495.
26. Fourtillan JB, Brisson AM, Gobin P., et al. Bioavailability of melatonin in humans after day-time administration of D7 melatonin. Biopharm Drug Dispos. 2000 ; 21: 15-22.
27. Waldhauser F., Waldhauser M., Lieberman H., et al. Bioavailability of oral melatonin in humans. Neuroendocrinology. 1984 ; 39: 307-313.
28. Lane EA, Moss HB Pharmacokinetics of melatonin in man: first pass hepatic metabolism. J Clin Endocrinol Metab. 1985 ; 61: 1214-1216.
29. Granfors MT, Backman JT, Neuvonen M., et al. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. Clin Pharmacol Ther. 2004 ; 75: 331-341.
30. Greenblatt JD, Harmatz JS, Karim A. Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT 1 and MT2. J Clin Pharmacol. 2007 ; 47: 485.
31. Hartter S., Nordmark A., Rose DM, et al. Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. Br J Clin Pharmacol. 2003 ; 56: 679-682.
32. Fourtillan JB, Brisson AM, Fourtillan M., et al. Melatonin secretion occurs at a constant rate in both young and older men and women. Am J Physiol Endocrinol Metab. 2001 ; 280: E11 - E22.
33. Cavallo A., Ritschel WA Pharmacokinetics of melatonin in human sexual maturation. J Clin Endocrinol Metab. 1996 ; 81: 1882-1886.
34. Mallo C., Zaidan R., Galy G., et al. Pharmacokinetics of melatonin in man after intravenous infusion and bolus injection. Eur J Clin Pharmacol. 1990 ; 38: 297-301.
35. DeMuro RL, Nafziger AN, Blask DE, et al. The absolute bioavailability of oral melatonin. J Clin Pharmacol. 2000 ; 40: 781-784.
36. Aldhous M., Franey C., Wright J., et al. Plasma concentration of melatonin in man following oral absorption of different preparations. Br J Clin Pharmacol. 1985 ; 19: 517-521.
37. Shirakawa S., Tsuchiya S., Tsutsumi Y., et al. Time course of saliva and serum melatonin levels after ingestion of melatonin. Psychiatry Clin Neurosci. 1998 ; 52: 266-267.
38. Di WL, Kadva A., Johnston A., et al. Variable bioavailability of oral melatonin. N Engl J Med. 1997 ; 336: 1028-1029.
39. Mones J., Carrio I., Estorch M., et al. Influence of the menstrual cycle and of menopause on the gastric emptying rate of solids in female volunteers. Eur J Nucl Med. 1993 ; 20: 600-602.
40. Lissoni P., Crispino S., Barni S., et al. Pineal gland and tumor cell kinetics: serum levels of melatonin in relation with Ki-67 labeling rate in breast cancer. Oncology. 1990 ; 47: 275-277.
41. Bartsch C., Bartsch H., Fuchs U., et al. Stage-dependent depression of melatonin in patients with primary breast cancer: correlation with prolactin, thyroid stimulating hormone and steroid receptors. Cancer. 1989 ; 64: 426-433.